Premium
Allogeneic haematopoietic stem cell transplantation for the treatment of adult T‐cell leukaemia/lymphoma
Author(s) -
Kami Masahiro,
Hamaki Tamae,
Miyakoshi Shigesaburo,
Murashige Naoko,
Kanda Yoshinobu,
Tanosaki Ryuji,
Takaue Yoichi,
Taniguchi Shuichi,
Hirai Hisamaru,
Ozawa Keiya,
Kasai Masaharu
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04054.x
Subject(s) - medicine , lymphoma , transplantation , haematopoiesis , hematopoietic stem cell transplantation , stem cell , disease , oncology , hematology , graft versus host disease , gastroenterology , immunology , biology , genetics
Summary. The feasibility of allogeneic haematopoietic stem‐cell transplantation (allo‐HSCT) in 11 patients with adult T‐cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced‐intensity) were tolerable. Five patients developed acute graft‐versus‐host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1‐year overall and disease‐free survival rates were 53 ± 30% and 45 ± 29% respectively. Four patients remain alive and disease‐free at a median follow‐up of 25 months. The others died of transplantation‐related complications. This pilot study suggests that allo‐HSCT in ATL should be evaluated further.